Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.04%
#2 Ocean Protocol Ocean Protocol +22.42%
#3 Audiera Audiera +15.20%
#4 Geodnet Geodnet +14.73%
#5 Arowana Arowana +7.85%
#6 DexNet DexNet +7.78%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +7.71%
#8 Ontology Gas Ontology Gas +6.77%
#9 Rollbit Coin Rollbit Coin +6.27%
#10 Cysic Cysic +6.18%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
Spago Nanomedical AB (publ) Spago Nanomedical AB (publ)

Spago Nanomedical AB (publ)

SPAGO
Rank in Stocks #32285
Operating primarily in Sweden, Spago Nanomedical AB (publ) is dedicated to... Operating primarily in Sweden, Spago Nanomedical AB (publ) is dedicated to pioneering nanomedicines for both the diagnosis and treatment of cancer. The company is actively pursuing two key projects: the SpagoPix initiative, centered on SN132D, a gadolinium-free MRI contrast agent developed for imaging breast and pancreatic cancers; and the Tumorad project, which is advancing SN201, a radionuclide therapy intended for managing advanced and metastatic forms of cancer. Originally established as Spago Imaging AB (publ), the company adopted its current name, Spago Nanomedical AB (publ), in May 2014. Founded in 1999, its base of operations is situated in Lund, Sweden.
Share Price
$0.01317984
Last synced: 2026-08-17
Market Cap
$10.52M
Change (1 day)
-1.26%
Change (1 year)
-53.51%
Country
SE
Trade Spago Nanomedical AB (publ) (SPAGO)

Category

Healthcare
P/E ratio for Spago Nanomedical AB (publ) (SPAGO)
P/E ratio as of 2026 TTM: 0
According to Spago Nanomedical AB (publ) latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Spago Nanomedical AB (publ) from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.